Archive · 2 Jun 2025
Systematix Analyst Bullish on Pharma Stocks
A Systematix Group analyst, Vishal Manchanda, is recommending specific pharmaceutical companies for investment.
He likes Sun Pharmaceutical Industries for its long-term growth potential, focusing on its specialty platform.
He also favors Cipla, due to its lower dependence on the US market and a promising product pipeline.
In the small-cap sector, Orchid Pharma is his top pick.
Manchanda also highlights Shilpa Medicare's upcoming product launches and CDMO platform.
Panacea Biotec is also mentioned for its potential dengue vaccine.
Vishal Manchanda of Systematix Group recommends pharma stocks for long-term growth.
Sun Pharma is favored for its specialty platform and growth visibility.
Cipla is highlighted for its limited US market reliance and product pipeline.
Orchid Pharma is Manchanda's preferred small-cap pick.
Shilpa Medicare has upcoming product launches and a growing CDMO platform.
- Who
- Vishal Manchanda of Systematix Group.
- What
- Analyst recommendations for pharmaceutical stocks.
- When
- N/A
- Where
- N/A
- Why
- Due to long-term structural opportunities and growth potential.
- Analyst
- Vishal Manchanda, Systematix Group
- Large-cap picks
- Sun Pharma, Cipla
- Small-cap pick
- Orchid Pharma
- Shilpa Medicare
- Upcoming product launches & CDMO platform
- Panacea Biotec
- Dengue vaccine development underway